{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:53:08Z","timestamp":1698972788940},"reference-count":17,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":857,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:p>Laropiprant (LRPT), a prostaglandin D<jats:sub>2<\/jats:sub> receptor\u20101 antagonist shown to reduce niacin\u2010induced flushing symptoms, has been combined with niacin for treatment of dyslipidemia. This study evaluated the effects of LRPT (50 mg and 600 mg, respectively) on the QT interval with Fridericia's correction (QTcF). QTcF measurements were made over a 24\u2010hour period following administration of single\u2010dose moxifloxacin 400 mg, LRPT 50 mg, LRPT 600 mg, or placebo. The primary hypothesis was supported if the 90% confidence intervals (CIs) for the least squares (LS) mean differences between placebo and LRPT in change from baseline in QTcF interval were &lt;10 milliseconds at every time point. The upper limits of the 90% CIs for LS mean differences from placebo in changes from baseline in QTcF intervals for LRPT 50 mg and 600 mg were &lt;5 milliseconds at every time point. The lower limits of the 90% CIs for placebo\u2010adjusted LS mean changes from baseline in QTcF intervals for moxifloxacin exceeded 0 milliseconds at every time point, demonstrating the sensitivity of this assay to detect increases in the QTcF interval. In conclusion, single doses of LRPT 50 mg and 600 mg do not prolong the QTcF interval relative to placebo and are generally well tolerated.<\/jats:p>","DOI":"10.1177\/0091270009360042","type":"journal-article","created":{"date-parts":[[2010,1,28]],"date-time":"2010-01-28T03:21:26Z","timestamp":1264648886000},"page":"1273-1279","source":"Crossref","is-referenced-by-count":2,"title":["Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D<sub>2<\/sub> Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers"],"prefix":"10.1002","volume":"50","author":[{"given":"Wen\u2010Lin","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tami","family":"Crumley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Atiee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Royalty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy O.","family":"Johnson\u2010Levonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eseng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2005.01528.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-000-0096-y"},{"key":"e_1_2_5_4_2","first-page":"229","article-title":"Increasing HDL cholesterol with extended\u2010release nicotinic acid: from promise to practice","volume":"62","author":"Birjmohun RS","year":"2004","journal-title":"Neth J Med"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00732-2"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-3-4"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-6980(89)90088-9"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12499963"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)92627-1"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.170"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700586"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601574103"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.106.030833"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.10.023"},{"key":"e_1_2_5_15_2","unstructured":"European Medicines Agency.International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs: E14. Geneva Switzerland;2005.http:www.ich.orgLOBmediaMEDIA1476.pdf. Accessed September 30 2009."},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008318007"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100345"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.014696"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270009360042","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270009360042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T14:24:56Z","timestamp":1698935096000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270009360042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1177\/0091270009360042"],"URL":"https:\/\/doi.org\/10.1177\/0091270009360042","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}